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Abstract
Protein-based breast cancer biomarkers are a promising resource
for breast cancer detection at the earliest and most treatable
stages of the disease. Plasma is well suited to proteomic-based
methods of biomarker discovery because it is easily obtained, is
routinely used in the diagnosis of many diseases, and has a rich
proteome. However, due to the vast dynamic range in protein
concentration and the often uncertain tissue and cellular origin of
plasma proteins, proteomic analysis of plasma requires special
consideration compared with tissue and cultured cells. This review
briefly touches on the search for plasma-based protein biomarkers
for the early detection and treatment of breast cancer.
Introduction
Early detection decreases breast cancer-related mortality [1],
and breast cancer biomarkers offer a promising means to
detect this disease at the earliest and most treatable stages.
Both plasma and serum (collectively referred to as ‘plasma’ in
the following discussion for simplicity) are excellent sources
of clinically relevant sample material for the early detection of
breast cancer. Plasma is easily obtained, is routinely used in
the diagnosis of many diseases, and has a rich proteome [2].
Thus, plasma is well suited to proteomics based methods of
biomarker discovery and may be a rich source of protein-
based biomarkers for the early detection of cancer. Examples
of such biomarkers include prostate-specific antigen and CA-
125, which are used to detect prostate and ovarian cancers,
respectively [3,4]. However, while there are hundreds of
unvalidated candidate biomarkers for the detection and
treatment of breast cancer, there are currently no validated
plasma markers in clinical use for the early detection of breast
cancer. Furthermore, only a handful of biomarkers are used in
its diagnosis and prognosis; examples include HER-2/neu,
estrogen receptor, and progesterone receptor. Therefore
instead of discussing numerous unvalidated candidates, this
review is intended as a brief conceptual introduction to the
proteomic search for plasma-based biomarkers that may be
used in the early detection and therapy of breast cancer.
Proteomic analysis of plasma
In general, there are two approaches to proteomic biomarker
discovery: target specific and global/nondirected (Table 1)
[5]. Target-specific approaches often use antibodies to screen
specific proteins through western blot analysis, enzyme-linked
immunosorbent assays, and antibody arrays, to name a few.
While these techniques are clinically applicable, they are
generally low-throughput with regard to the number of
proteins that can be surveyed at any one time. Thus, they may
not be ideal for biomarker discovery. In contrast, global/
nondirected approaches may be better suited for biomarker
discovery because they are relatively unbiased, high-through-
put screens. Nondirected approaches can also be divided
into two groups: those studies that rely on profiling of
unidentified proteins and those that generate profiles of
identified proteins [6].
Protein profiling of unidentified proteins is often, although not
exclusively, accomplished through matrix-assisted laser
desorption/ionization (MALDI) time-of-flight (TOF) mass
spectrometry (MS) or surface-enhanced laser desorption/
ionization (SELDI)-TOF-MS [6]. In MALDI-TOF-MS, small
protein fragments or peptides are crystallized within a solid
matrix, which is bombarded with a laser to ionize the
peptides. The ionized peptides are separated by TOF, in
which smaller, less charged particles move through a flight
tube faster than do larger ones with greater charge. These
particles are analyzed via MS to generate a spectrum of
mass/charge peaks. The peak intensities in case and control
samples are then compared in order to define a pattern of
peaks that can segregate case from control samples. SELDI-
TOF-MS differs from MALDI-TOF-MS in that peptides are
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bound to a solid support through such mechanisms as
electrostatic or hydrophobic/hydrophilic forces, rather than
being immobilized within a crystalline matrix. Then, nonbound
peptides are washed away, thereby cleaning and simplifying
the samples to be analyzed. As a result, the number of
proteins identified may actually be increased (see below) as
compared with MALDI.
The main advantage of MALDI and SELDI is their speed.
Many samples can be processed in a short period of time,
thus making them attractive tools for clinical screening.
Because peptides of interest are not typically identified,
validation through other techniques is difficult. However, with
additional steps, peaks (proteins) of interest can be identified.
Proteins are typically identified using tandem MS, which
separates and fragments peptides in multiple stages. The
MS-derived fragmentation patterns are used to determine the
exact amino acid sequence for a peptide of interest. Before
the human genome had been sequenced, peptide sequences
were determined manually based on generated mass/charge
spectra; this de novo sequencing was extremely time
consuming and error prone. In the postgenomic era, however,
we can compare the spectra of observed peptides with those
of peptides that are determined from the theoretical gene
products of the entire genome. This process of peptide
identification is much quicker and more accurate than de
novo sequencing and makes high-throughput proteomics a
reality. Although it is much faster than de novo sequencing,
protein identification is still slower than the profiling-based
proteomic studies mentioned above, which do not rely on
peptide fragmentation or database searches to identify peaks
of interest. However, it must be noted that protein profiles are
also generated from proteins identified through tandem MS
based analysis of a sample of interest. This is a laborious
process but can provide much information.
MS-based proteomic methods offer an unbiased view of a
sample’s proteome, but they suffer a significant limitation.
Specifically, even the best mass spectrometers have an
analytical dynamic range of only a few orders of magnitude.
Therefore, in a single analytical run it is difficult to detect
proteins within the microgram/milliliter range, where many
biomarkers are thought to reside. This is because of the fact
that plasma contains proteins, such as albumin, that are
50,000 times more abundant than the potential biomarkers in
the microgram/milliliter range [2]. Furthermore, because
plasma may contain proteins with concentrations covering 10
orders of magnitude [2], a significant fraction of proteins will
remain undetected. To overcome the limitations associated
with the small analytical dynamic range of mass
spectrometers, much work is aimed at reducing the
complexity of samples before analysis. This has been
accomplished most often through depletion/enrichment and
fractionation/separation.
Sample depletion/enrichment involves the specific removal or
purification of a subset of the proteome. For example,
Agilent’s Multiple Affinity Removal System (MARS) is a
reusable immunodepletion column that uses antibodies to
remove the six most abundant plasma proteins: albumin, IgG,
IgA, transferrin, haptoglobin, and antitrypsin. These six
proteins account for 90% of plasma protein content by mass.
Their removal effectively decreases the concentration at
which we can detect plasma proteins by two orders of
magnitude. Alternatively, phosphoproteins can be enriched by
capturing them with phospho-specific antibodies [7], and
glycoproteins can be enriched/depleted with a lectin-based
pull down system [8]. The latter was designed to reduce
plasma complexity because many plasma constituents are
glycoproteins. Of possible concern, sample depletion may
remove potential biomarkers. For instance, albumin is a
known carrier of plasma proteins and may bind potential
Table 1
Summary of proteomic approaches used to analyze plasma for breast cancer biomarkers
Approaches Examples Pros Cons
Nondirected/global Identification based Tandem MS Unbiased searches Requires fractionation and/or 
Protein identities are determined depletion/enrichment to overcome 
Highly reproducible limited dynamic range
Time intensive
Pattern based MALDI-TOF-MS High throughput Protein identities not determined, 
Potentially applicable for clinical  making validation difficult 
use Identified proteins have been 
Unbiased searches high-abundance immune and 
clotting factors
Low reproducibility between 
laboratories
Target specific Western/ELISA/ Relatively high throughput Limited antibody availability 
antibody arrays Clinically applicable Untargeted proteins will remain 
Identity of proteins is known undetected
ELISA, enzyme-linked immunoisorbent assay; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; TOF, time-of-flight.Page 3 of 4
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biomarkers. However, when combined with fractionation, the
number of additional proteins identified after depletion of
albumin far outweighs the number of proteins that are
potentially lost. Furthermore, the pool of depleted proteins
can be analyzed for the presence of candidate biomarkers
that have bound the captured proteins. Therefore, little to no
data should be lost through depletion.
Sample fractionation/separation for proteomic analysis has
most often been accomplished through two-dimensional gel
electrophoresis, in which samples are separated electro-
phoretically based on isoelectric point and size. Samples are
visualized as spots using protein stains, autoradiography, or
fluorescent tags. There are many variations of this technique,
but traditionally gels/membranes from cases are compared
with those from controls to identify differences between the
two. Proteins of interest are excised, digested with a protease
such as trypsin, and then analyzed by MS. Of note, two-
dimensional gel electrophoresis can separate the individual
species of a protein, such as isoforms, fragments, and
modifications. However, other techniques may be necessary
to determine which particular species have been identified.
One drawback of two-dimensional gel electrophoresis is its
low sensitivity, which is limited by the ability to visualize a
protein on the gel/membrane. Thus, two-dimensional gel
electrophoresis suffers from a small analytical dynamic range.
In addition, it also suffers from the limited range of protein
species that can be resolved in a single run due to physio-
chemical properties such as size, charge, or post-translational
modifications.
Due to the limitations of two-dimensional gel electrophoresis,
a growing number of researchers are using liquid chromato-
graphy to fractionate proteins before MS analysis. In this
method, proteins are first digested into peptides. The
peptides are separate based on net positive or net negative
charge using a strong cation or anion exchange column,
respectively. Alternatively, peptides are separated by
hydrophobicity using a reversed-phase column. The beauty of
this system is the ability to combine these two separation
methods for multidimensional peptide separation. For
example, fractions collected from the cation/anion exchange
column are further separated by reversed-phase chromato-
graphy. Each fraction is then analyzed by MS. Because each
fraction is significantly less complex than whole plasma, many
more proteins and more low-abundance proteins are
identified. However, this method also significantly increases
the time needed for MS analysis. Abundance differences in
protein isoforms, degradation fragments, or post-translational
modifications may serve as biomarkers for early detection of
breast cancer, but it is impossible to discern one protein
species from another when proteins are digested before
separation. Thus, some groups, including our own, have
opted to separate intact proteins before digestion [9,10]. In
this manner, the information regarding changes in individual
protein species is conserved, and we can routinely identify
well over 1000 proteins and their protein subspecies
(isoforms, cleavage fragments, and so on).
Tumor and tissue specificity
One goal of biomarker research is to identify markers that are
tumor specific. Unfortunately, plasma-based proteomics
suffers from the fact that proteins within plasma originate
from numerous tissues. For example, when studies report an
upregulation of interleukin-6 in the serum of breast cancer
patients compaed with control individuals, it is difficult to
know whether this protein is released directly from the tumor
or whether interleukin-6 upregulation is a systemic reaction to
the tumor and released by nontumor tissues [11].
Therefore, when searching for tumor-specific biomarkers, it is
necessary to consider how tumor proteins appear in the
blood. Possibilities include the following: increased expression
of secreted and membrane-bound proteins; loss of polarity,
resulting in apical secretion of basal proteins and vice versa;
increased cleavage of matrix and membrane-bound proteins
caused by increased protease expression and/or activation;
and release of cytoplasmic proteins from cells that have died.
The latter possibility may be unlikely, given the findings of a
recent report presenting a proteomic analysis of tissue
interstitial fluid from breast tumors [12]. That study identified
few of the nuclear proteins that are so often identified in
proteomic analyses of cell lines and whole tissues. Based on
these observations, the authors hypothesized that cell lysis
does not significantly contribute to the proteomic content of
tumor tissue interstitial fluid. As an extension, it may be likely
that cell lysis also contributes little to the blood proteome of
cancer patients. Therefore, secreted proteins, matrix proteins,
and cleaved membrane-bound proteins may be the most
probable source of tumor-specific biomarkers. Additionally, as
stated above, tumor-specific plasma markers may result from
altered localization of proteins and protein fragments rather
than from increased expression. As a result, proteomic studies
may not correlate well with RNA expression studies.
Crucial to early detection, the biomarker field is seeking
markers that are tissue specific in addition to being tumor
specific. If we can detect the cancer but not the tissue of
origin, then we may actually do more harm than good, since
searching for a suspected tumor will add undo stress to the
patient and increased cost to the treatment. Finding tissue-
specific tumor markers has thus far proven difficult. Many
candidate biomarkers have been concurrently identified in
numerous tumor types. This likely reflects that fact that 90%
of all cancers are of epithelial origin and thus express many of
the same proteins [13]. It is probable that a panel of markers
will be required to establish tissue specificity rather than a
single protein; this panel may or may not be independent of a
tumor-specific panel of biomarkers. In addition, early
detection markers may need to be used in conjunction with
other screening methods, such as mammography, where the
tissue origin is not in question.
Available online http://breast-cancer-research.com/content/8/6/217Sample-dependent considerations
Although plasma is the specimen of choice for early
diagnosis, proteomic-based biomarker studies also rely on
cells grown in culture and tissue samples. Cells grown in
vitro provide ample material for analysis and are easily
manipulated with therapeutic agents. However, cells grown in
vitro behave quite differently from those in vivo [14], and
because cell lines are derived from a single person, it can be
difficult to generalize results to the population as a whole.
Tissue is also frequently used and is generally collected via
biopsy or mastectomy. Often, tissue sections with more than
50% or more than 70% tumor tissue are compared with
normal tissue sections. However, care must be taken
because most breast cancers are of epithelial origin, and
normal tissue sections with more than 50% epithelium may
be difficult to find. Thus, differences observed in many studies
may simply reflect differences in epithelial:stromal ratios
rather than differences between cancer and normal tissues.
Finally, tissue is heterogeneous, containing epithelium, fibro-
blasts, fat cells, endothelium, immune cells, and so on. These
differences can be difficult to control. To circumvent these
problems, many groups use laser capture microdissection
[15] to specifically capture equal numbers of cancer and
normal cells for analysis. Alternatively, imaging MS may allow
differentiation of stroma from epithelium within breast tissue,
although the 50 µm resolution of imaging MS may be too low
to distinguish epithelial ducts from the milieu of stroma that
comprises much of the mammary tissue [16,17].
When blood is used as sample material, the cells are
removed before analysis. This is accomplished with the
addition of anticoagulants such as EDTA followed by
centrifugation (plasma) or by allowing the blood to clot
followed by removal of the supernatant (serum). Some groups
prefer plasma over serum because the clotting process in
serum preparation may introduce inconsistencies and
significant sample-to-sample variation [2].
Conclusion
Disease-related proteomics is fueled by the hope that we
might literally save hundreds of thousands of lives per year
with markers of early detection and with markers that allow
optimized treatment for each individual. There are hundreds
of identified candidate biomarkers, but these must be
validated to prove their specificity and clinical relevance.
Thus, for breast cancer, we do not, as yet, have those golden
markers so actively sought. However, proteomics has come
far in the past decade, and numerous candidates are now
progressing through validation studies.
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